Publications
Specialty
Search
Pharmacy Learning Network
10/21/2024
In late September 2024, the Federal Trade Commission brought action against Caremark, Express Scripts, and OptumRx, the 3 largest pharmacy benefit managers and their respective group purchasing agents.
Vascular Disease Management, Journal of Invasive Cardiology
10/21/2024
Philips portfolio of image-guided therapy and echocardiography solutions uniquely integrates artificial intelligence into imaging systems and software, with specialized diagnostic and therapeutic devices to support exceptional treatment for even the most complex procedures.
The Philips Engagement Hub in Hall C at the Walter E. Washington Convention Center will feature numerous physician-led discussions, and hands-on trainings that address a range of key challenges in cardiology.
Vascular Disease Management, Journal of Invasive Cardiology
10/21/2024
Greater than 2-fold predictive value (p=0.001) for heart attack, stroke, and death
Significant unmet need in balancing the risks and benefits of antithrombotic treatment in patients with acute coronary syndrome (ACS)
Supports trend in individualized antiplatelet therapy
PHILADELPHIA, October 21, 2024 (Newswire.com) - Prolocor, Inc., a healthcare startup developing the innovative diagnostic Prolocor pFCG® test that identifies patients at higher and lower risk of thrombotic events (heart attack, stroke, and death), announced today the publication of res
First Report Managed Care
10/21/2024
A study published in the International Journal of Obesity found that gastric bypass surgery leads to significant long-term weight loss and metabolic changes, suggesting that maintaining fat-free mass may help sustain metabolic rates post-surgery.
Pharmacy Learning Network
10/21/2024
True or False: Lecanemab-IRMB (Leqembi™) is the second Alzheimer drug that has affected the course of the disease successfully in phase 3, had a low side effect profile and then got full FDA approval.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
10/21/2024
The LIBERATE phase 2b, randomized and double-blind study will include more than 212 patients suffering from STEMI who are scheduled to undergo PCI. The study’s primary objective is to assess the safety and efficacy of glenzocimab 1000 mg compared to placebo, in reducing the size of the myocardial infarction 90 days post-event.
Podiatry Today
10/21/2024
Together, we can help to develop advanced, cutting-edge therapies to help our at-risk patients.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular, Vascular Disease Management
10/21/2024
The Yale team found PVD occurred in 11% of patients with atopic dermatitis (AD), but just 6.2% of patients without AD.
Advances in Inflammatory Bowel Disease Network
10/21/2024
Dr Raymond Cross hosts Drs James Lewis and Laura Raffals in a discussion of SPARC, a study of adults with inflammatory bowel disease in which patients are followed prospectively to collect data about to allow prediction of disease course and advance the field in IBD.
Lymphoma, Leukemia & Myeloma Network, Oncology
10/19/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Daniel Landsburg, MD, participated in a debate where he argued in favor of utilizing CAR T-cell therapy to treat patients with relapsed/refractory follicular lymphoma.
Lymphoma, Leukemia & Myeloma Network, Oncology
10/19/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Joshua Richter, MD, discusses the role of measurable residual disease in the treatment of patients with multiple myeloma.
EP Lab Digest
10/18/2024
The Heart Rhythm Society (HRS) Board of Trustees unanimously approved the formation of Heart Rhythm Advocates, a new, shared vision, cause-related nonprofit 501(c)(4) advocacy organization to complement the primary 501(c)(3) nonprofit structure of the HRS.
EP Lab Digest
10/18/2024
Tenaya Therapeutics Press Release
EP Lab Digest
10/18/2024
Boston Scientific Press Release
Pharmacy Learning Network
10/18/2024
A new study published in Nature Communications has provided crucial insights into the structure and organization of respiratory syncytial virus (RSV).
First Report Managed Care
10/18/2024
Learn about the impact of the 2024 Homecare Insights Survey on caregiver satisfaction and how specialized training, recognition, and technology can enhance patient care and support caregiver well-being.
First Report Managed Care
10/18/2024
Explore the implications of the CY 2025 Medicare Part D Redesign and the Inflation Reduction Act with AMCP Nexus 2024 session speakers, addressing successes and challenges faced by stakeholders as they prepare for significant changes ahead.
IO Learning
10/18/2024
At the 2024 Symposium on Clinical Interventional Oncology, Ed Kim, MD, moderated a session titled “The Wave of the Future: New Technologies or the IR”, featuring presentations on conformable embolic and robotics by Dr Kim, Osman Ahmed, MD, and Gina Landinez, MD.
Oncology
10/18/2024
Based on results from the SPOTLIGHT and GLOW trials, the FDA has approved first-line zolbetuximab plus fluoropyrimidine and platinum-containing chemotherapy for patients with locally advanced, unresectable, or metastatic HER2-negative gastric or gastroesophageal cancer junction adenocarcinoma who are CLDN18.2-positive.
EMSWorld, Emergency & Mobile Medicine
10/18/2024
Let’s shed those sacred cows and embrace a new era of EMS—one where expertise and efficiency drive our success.
Reimbursement Library From A to Z
Subscribe and never miss an article!
Today's Wound Clinic Newsletter
